West Chester, PA, United States of America

Lin You

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Incyte Corporation. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lin You. Retrieved from https://idiyas.com/inventor/lin-you-1mpx12ti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lin You: Innovator in Bicyclic Amine CDK12 Inhibitors

Introduction

Lin You is a prominent inventor based in West Chester, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors that target specific biological pathways.

Latest Patents

Lin You holds a patent for "Bicyclic Amine CDK12 Inhibitors." This innovative work focuses on creating compounds that can effectively inhibit the CDK12 enzyme, which plays a crucial role in various cellular processes.

Career Highlights

Lin You is currently employed at Incyte Corporation, a leading biopharmaceutical company. His work at Incyte has allowed him to contribute to groundbreaking research and development in the field of cancer therapeutics.

Collaborations

Lin has collaborated with notable colleagues, including Xin Li and Michael Liang. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Lin You is a dedicated inventor whose work in bicyclic amine CDK12 inhibitors exemplifies the impact of innovative research in the pharmaceutical industry. His contributions continue to advance the field and hold promise for future therapeutic developments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…